NSCLC_RWE_(Concerto)_Supplementary_Tables.docx (36.77 kB)
Download file

IMT-2021-0145 Supplementary Tables

Download (36.77 kB)
dataset
posted on 04.08.2021, 10:47 by Figshare Future Science GroupFigshare Future Science Group, Xinke Zhang, Richard W. DeClue, Lisa Herms, Mo Yang, Vivek Pawar, Elizabeth T. Masters, Mary Ruisi, Kevin Chin, Vamsidhar Velcheti

Supplementary Table 1. 1L treatments received by treatment class (N=501)

Supplementary Table 2. Reasons for end of follow-up for patients who did not receive 2L treatment

Supplementary Table 3. Subgroup analysis of median OS (N=501)

Supplementary Table 4. Adjusted cox regression analysis of treatment outcomes for 1L treatment groups


Background

We report real-world treatment patterns and outcomes in patients with PD-L1+ NSCLC.

Methods

This retrospective, observational study using the ConcertAI Oncology Dataset, included patients with PD-L1+ (≥1% expression) metastatic NSCLC who began first-line (1L) treatment between 2016-2019. Treatment outcomes were assessed by treatment class (immune checkpoint inhibitor [ICI] monotherapy, ICI combinations, or chemotherapy).

Results

In total, 128 (25.5%), 237 (47.3%) and 136 patients (27.1%) received 1L chemotherapy, 1L ICI monotherapy, and 1L ICI combinations, respectively. ICI combinations and monotherapy had improved clinical outcomes vs chemotherapy. Adjusted analyses showed no significant difference in outcome between ICI monotherapy and ICI combinations.

Conclusion

ICI-based treatments are being increasingly adopted into clinical practice and were associated with better outcomes vs chemotherapy.

Funding

Merck KGaA, Darmstadt, Germany

Pfizer

History